3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
68
Recurrence
7
Smoldering Multiple Myeloma
4
Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Plasmacytoma
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
40
Magnetic Resonance Spectroscopy
19
Radiotherapy
18
Specimen Handling
14
Radiation
12
Bevacizumab
11
Lomustine
9
pembrolizumab
6
fludarabine
5
Surgical Procedures, Operative
5
atezolizumab
4
Nivolumab
4
Ipilimumab
4
Cyclophosphamide
4
Carboplatin
4
Biopsy
4
cemiplimab
3
azeliragon
3
Immunoglobulin G
3
Disulfides
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
rocakinogene sifuplasmid
2
poly ICLC
2
olaparib
2
lutetium Lu 177 dotatate
2
durvalumab
2
dabrafenib
2
contrast agent BR1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
daratumumab
×
90 days
×
Clear all
NCT04922723
2026-04-28
PRIDE
West Virginia University
Phase 1/2
Active not recruiting
16 enrolled